Anavex Life Sciences Corp (AVXL)

[bas2020]

So, you don't think that the PDD data will be included with the AD data in the peer-reviewed journal? Since the two are closely related, it would seem a good opportunity to provide a comprehensive analysis of blarcamesine's efficacy & safety with the implication that it'll be effective therapy in addressing multiple degenerative CNS indications.

I think there's a distinct possibility.